Result of AGM

Hutchison China Meditech Limited
11 May 2007


                  Hutchison China MediTech Limited ('Chi-Med')
                                   (AIM: HCM)

                       Results of Annual General Meeting

London, Friday, 11 May 2007: Chi-Med is pleased to announce that all ordinary
resolutions put to its Annual General Meeting ('AGM') held on 11 May 2007 were
duly passed and the poll results of the resolutions were as follows:

                                                                           Number of Votes (%)

Ordinary Resolutions                                                  For        Against      Withheld

1      To receive and consider the audited financial statements   40,537,607        0             0
       and the reports of the directors and independent auditor      (100%)        (0%)         (0%)
       for the year ended 31 December 2006.                          

2(a)   To re-elect Mr. Christian Hogg as a director.              40,437,607        0             0
                                                                     (100%)        (0%)         (0%)

2(b)   To re-elect Mr. Patrick Wan as a director.                 40,537,607        0             0
                                                                     (100%)        (0%)         (0%)

2(c)   To re-elect Mr. Christian Salbaing as a director.          40,537,607        0             0
                                                                     (100%)        (0%)         (0%)

2(d)   To re-elect Ms. Edith Shih as a director.                  40,537,607        0             0
                                                                     (100%)        (0%)         (0%)

2(e)   To re-elect Mr. Michael Howell as a director.              40,537,607        0             0
                                                                     (100%)        (0%)         (0%)

2(f)   To re-elect Prof. Christopher Huang as a director.         40,537,607        0             0
                                                                     (100%)        (0%)         (0%)

2(g)   To re-elect Mr. Christopher Nash as a director.            40,537,607        0             0
                                                                     (100%)        (0%)         (0%)

3      To re-appoint PricewaterhouseCoopers as the auditor of     40,537,607        0             0
       the Company and authorise the board of directors to fix       (100%)        (0%)         (0%)
       the auditor's remuneration.                                   

4(a)   Ordinary resolution on item 4(A) of the Notice of the      40,537,607        0             0
       Meeting (To grant a general mandate to the directors of       (100%)        (0%)         (0%)
       the Company to issue additional shares)                       

4(b)   Ordinary resolution on item 4(B) of the Notice of the      40,537,607        0             0
       Meeting (To grant a general mandate to the directors of       (100%)        (0%)         (0%)
       the Company to repurchase shares of the Company)              

5      Ordinary resolution on item 5 of the Notice of the         40,537,607        0             0
       Meeting                                                       (100%)        (0%)         (0%)
       (To extend the general mandate to the directors of the
       Company to issue additional shares)

As at the date of the AGM, the number of issued shares of Chi-Med was 51,212,121
shares, which was the total number of shares entitling the holders to attend and
vote on the resolutions proposed at the AGM.


                                      Ends


Enquiries

Citigate Dewe Rogerson                 Telephone: [phone]

Anthony Carlisle                       [phone]
Yvonne Alexander                       [phone]


About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based
primarily in China and was admitted to trading on the Alternative Investment
Market of the London Stock Exchange in May 2006. Chi-Med is focused on
researching, developing, manufacturing, and selling pharmaceuticals, health
supplements and other consumer health and personal care products derived from
Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international
corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.




                      This information is provided by RNS
            The company news service from the London Stock Exchange